Medpace Holdings, Inc. (MEDP) has a MoatMap StockRank of 60/100 based on Quality (75/100), Value (32/100), and Momentum (37/100) factor scores. The current signal is HOLD. Medpace Holdings, a Clinical Research Organization (CRO), is a high-quality compounder perfectly aligned with the 'Durable Quality & Moats' macro theme. Its asset-light, service-based model generates high returns on capital, and pharmaceutical clients face significant switching costs. However, it lacks a direct, powerful macro *inflection point* that the market has significantly underpriced from the current geopolitical and energy security events, making it a less asymmetric opportunity than those with more direct macro tailwinds.
Medpace Holdings, Inc. is a global, full-service clinical contract research organization (CRO) providing clinical development services to biopharmaceutical and medical device companies. The company specializes in scientifically-driven clinical trials, particularly for small to mid-sized biopharma firms, offering a comprehensive and integrated approach. Its deep therapeutic expertise, operational efficiency, and focus on complex, high-quality trials provide a strong competitive moat within the specialized CRO market.
| Price | $451.47 |
| Market Cap | $12.8B |
| P/E (TTM) | 27.02 |
| P/E (Forward) | 23.12 |
| Price/Book | 20.48 |
| Return on Equity | 77.3% |
| Return on Invested Capital | 84.7% |
| Debt/Equity | 24.42 |
| Gross Margin | 71.9% |
| Operating Margin | 20.0% |
| Revenue Growth | 26.5% |
| Free Cash Flow | $491M |
Medpace Holdings, Inc. operates in the Diagnostics & Research industry, part of the Healthcare sector (United States).